REFERENCES
- Cazzola M, Matera MG, Donner CF. Pharmacokinetics and pharmacodynamics of newer oral cephalosporins: implica-tion for treatment of community-acquired lower respiratory tract infections. Clin Drug Invest 1998; 16: 335–346.
- Craig WA, Andes D. Pharmacokinetics and pharmaco-dynamics of antibiotics in acute otitis media. Pediatr Infect Dis J 1996; 15 (Suppl 3): 255–259.
- Preston DA. Global surveillance of bacterial susceptibility to cefaclor: 1988-1990. Clin Ther 1993; 15: 88–96.
- Cazzola M. Problems and perspectives in the antibiotic treatment of lower respiratory tract infections. Pulm Pharmacol 1994; 7: 139–152.
- Brumfitt W, Hamilton-Miller JMT. Cefaclor into the mil-lennium. J Chemother 1999; 11: 163–178.
- Brumfitt W. Introductory remarks. Postgrad Med J 1992; 68 (Suppl 3): S1–S2.
- Cazzola M, Matera MG, Cirella M, et al. Penetrazione del cefaclor nell'espettorato dopo somministrazione singola e multipla: confronto fra la preparazione a rilascio classico e una formulazione a rilascio modificato. Giorn It Ric Clin Ter 1995; 16: 37–41.
- American Thoracic Society. Standards for the diagnosis and care of patients with chronic obstructive pulmonary dis-ease. Am J Respir Crit Care Med 1995; 152: S72–S120.
- Chapin-Robertson K, Edberg SC. Measurement of antibiotics in human body fluid: techniques and significance. In: Lorian V, ed. Antibiotics in laboratory medicine. 3rd ed. Baltimore: The Williams & Wilkins Co, 1991: 313.
- Forrest A, Chodosh S, Amantea MA, Collins DA, Schentag JJ. Pharmacokinetics and pharmacodynamics of oral grepafloxacin in patients with acute bacterial exacerbations of chronic bronchitis. J Antimicrob Chemother 1997; 40 ( Suppl A): 45-57.
- Hyatt JM, McKinnon PS, Zimmer GS, Schentag JJ. The importance of pharmacokinetic/pharmacodynamic surro-gate markers to outcome. Focus on antibacterial agents. Clin Pharmacokinet 1995; 28: 143–160.
- Craig WA. Choosing an antibiotic on the basis of phar-macodynamics. Ear Nose Throat J 1998; 77 (6 Suppl): 7–11.
- Highet VS, Forrest A, Ballow CH, Schentag JJ. Antibiotic dosing issues in lower respiratory tract infection: population-derived area under inhibitory curve is predictive of efficacy. J Antimicrob Chemother 1999; 43 ( Suppl A): 55-63.
- Cazzola M, Diamare F, Vinciguerra A, Salzillo A, Calderaro F. La penetrazione polmonare degli antibiotici e il suo impatto clinico. Rass Pat App Respir 1996; 11: 134–147.
- Cars O. Efficacy of b-lactam antibiotics: integration of pharmacokinetics and pharmacodynamics. Diagn Microbiol Infect Dis 1997; 27: 29–33.
- Peterson LR, Hall WH, Zinneman HH, Gerding DN. Standardization of a preparative ultracentrifuge method for quantitative determination or protein binding of seven antibi-otics. J Infect Dis 1977; 136: 778–783.
- Cappelletty DM, Rybak MJ. Bactericidal activities of cefprozil, penicillin, cefaclor, cefixime, and loracarbef against penicillin-susceptible and -resistant Streptococcus pneumoni-ae in an in vitro pharmacodynamic infection model. Antimicrob Agents Chemother 1996; 40: 1148–1152.
- Verhaegen J, Verbist L. In-vitro activity of 21 beta-lac-tam antibiotics against penicillin-susceptible and penicillin-resis-tant Streptococcus pneumoniae. J Antimicrob Chemother 1998; 41: 381–385.
- Acar JF. Resistance patterns of Haemophilus influen-zae. J Chemother 1999; 11 (Suppl 1): 44–50.
- Garau J. Basing empiric treatment choices for respira-tory tract infection on the results of the Alexander Project. J Chemother 1999; 11 (Suppl 1): 51–55.
- Cazzola M, Matera MG. Interrelationship between phar-macokinetics and pharmacodynamics in the design of dosage regimens for treating acute exacerbations of chronic bronchi-tis. Respir Med 1998; 92: 895–901.